

# Report Package: Hot targets for empowered antibody and cell therapy technologies

https://marketpublishers.com/r/R7CCE445BF2EN.html Date: December 2016 Pages: 202 Price: US\$ 2,090.00 (Single User License) ID: R7CCE445BF2EN **Abstracts** Report Package: Hot targets for empowered antibody and cell therapy technologies This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets for the successful application of empowered antibody and cell technologies, including: Fc-Engineered Antibodies; Radioimmunotherapy;


Antibody-Drug Conjugates;

Immunotoxins;

T-Cell Redirecting Bispecific Antibodies;

Chimeric Antigen Receptor (CAR) T-Cells.





Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

CD123: a paradigmatic target for immunotherapeutic treatment modalities

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.



### **Contents**

#### **REPORT 1:**

## B-CELL MATURATION ANTIGEN (BCMA): HOT TARGET FOR EMERGING TREATMENT MODALITIES

**Target Background** 

Target Antigen Expression Profile

Preclinical Proof-of-Concept

Clinical Indications & Treatment Options

Clinical Experience with BCMA-Targeted Treatment Modalities

Treatment Modalities & Competitive Landscape

**Drug & Cell Therapy Candidate Profiles** 

**CAR T-Cells** 

Antibody-Drug Conjugate (ADC)

T-Cell Redirecting Antibodies

**Company Profiles** 

References

### **REPORT 2:**

# CD123: A PARADIGMATIC TARGET FOR IMMUNOTHERAPEUTIC TREATMENT MODALITIES

Target Background & Scientific Rationale

Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics

Clinical Experience with CD123-Targeted Treatment Modalities

Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics

Competitive Landscape

Profiles of Anti-CD123 Immunotherapeutics:

**Immunotoxins** 

**Naked Antibody** 

Fc-Engineered Antibodies

**Antibody-Drug Conjugates** 

T-Cell Redirecting Bispecific Antibodies

Anti-CD123 CAR T-Cells

**Company Profiles** 

References



ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

### **REPORT 3:**

### CD22: A SUITABLE ANTIGEN FOR TARGETED PAYLOAD DELIVERY BY IMMUNOTHERAPEUTICS

Target Background & Scientific Rationale

Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

Competitive Landscape

Profiles of Anti-CD22 Immunotherapeutics

Naked antibodies;

Radioimmunotherapy (RIT);

Immunotoxins (IT);

Antibody-Dug Conjugates (ADC); and

Chimeric Antigen Receptor (CAR) T-Cells.

Profiles of Companies with CD22-Targeted Immunotherapeutics

References

ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics



### I would like to order

Product name: Report Package: Hot targets for empowered antibody and cell therapy technologies

Product link: <a href="https://marketpublishers.com/r/R7CCE445BF2EN.html">https://marketpublishers.com/r/R7CCE445BF2EN.html</a>

Price: US\$ 2,090.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/R7CCE445BF2EN.html">https://marketpublishers.com/r/R7CCE445BF2EN.html</a>